GU Cancers 2026 | CREST: exploratory analysis of sasanlimab and BCG in very high-risk NMIBC
Felix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses exploratory results from the Phase III CREST trial (NCT04165317) of sasanlimab with BCG induction and maintenance in BCG-naive, high-risk non–muscle invasive bladder cancer (NMIBC). In patients with very high-risk disease, the combination demonstrated improved event-free survival compared with BCG alone, with consistent benefit across key subgroups and a manageable safety profile. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is very interesting because the CREST trial demonstrated a consistent benefit in the high-risk population when adding two years of Atezolizumab to two years of BCG induction plus maintenance and in the latest data they presented the subgroup of very high-risk patients where the EAU guidelines recommend radical cystectomy and we saw that the magnitude of the benefit is even higher in this group of patients...
This is very interesting because the CREST trial demonstrated a consistent benefit in the high-risk population when adding two years of Atezolizumab to two years of BCG induction plus maintenance and in the latest data they presented the subgroup of very high-risk patients where the EAU guidelines recommend radical cystectomy and we saw that the magnitude of the benefit is even higher in this group of patients. So this looks like a good alternative and maybe this population is more a candidate for the combination than other populations and thus trying to avoid first-line radical cystectomy with a combination of BCG plus atezolizumab.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
